Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

The D816V-mutated variant of Kit triggers multiple signaling pathways and is considered essential for malignant transformation in mast cell (MC) neoplasms. We here describe that constitutive activation of the Stat5-PI3K-Akt-cascade controls neoplastic MC development. Retrovirally transduced active Stat5 (cS5(F)) was found to trigger PI3K and Akt activation, and to transform murine bone marrow progenitors into tissue-infiltrating MCs. Primary neoplastic Kit D816V(+) MCs in patients with mastocytosis also displayed activated Stat5, which was found to localize to the cytoplasm and to form a signaling complex with PI3K, with consecutive Akt activation. Finally, the knock-down of either Stat5 or Akt activity resulted in growth inhibition of neoplastic Kit D816V(+) MCs. These data suggest that a downstream Stat5-PI3K-Akt signaling cascade is essential for Kit D816V-mediated growth and survival of neoplastic MCs.

[1]  E. Hsi,et al.  Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD. , 2007, Blood.

[2]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[3]  C. Pecquet,et al.  Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. , 2007, Blood.

[4]  J. Ryan,et al.  Stat5 Expression Is Required for IgE-Mediated Mast Cell Function1 , 2006, The Journal of Immunology.

[5]  R. Ilaria,et al.  STAT5 signaling is required for the efficient induction and maintenance of CML in mice. , 2006, Blood.

[6]  L. Hennighausen,et al.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. , 2006, Blood.

[7]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[8]  G. Delsol,et al.  Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation , 2005, The Journal of experimental medicine.

[9]  R. Roskoski.  Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[10]  C. Chen,et al.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.

[11]  C. Pecquet,et al.  Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter. , 2005, The Biochemical journal.

[12]  Doriano Fabbro,et al.  Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. , 2005, Blood.

[13]  S. Akira,et al.  Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis , 2005, The Journal of experimental medicine.

[14]  Kotaro Suzuki,et al.  Stat5a Is Essential for the Proliferation and Survival of Murine Mast Cells , 2005, International Archives of Allergy and Immunology.

[15]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[16]  C. Lam,et al.  Elevation of Plasma Soluble T Cell Costimulatory Molecules CTLA-4, CD28 and CD80 in Children with Allergic Asthma , 2005, International Archives of Allergy and Immunology.

[17]  V. Tybulewicz,et al.  Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. , 2005, Blood.

[18]  M. Tsai,et al.  Mast cells in the development of adaptive immune responses , 2005, Nature Immunology.

[19]  Giovanni Morrone,et al.  Constitutive Activation of STAT5A Promotes Human Hematopoietic Stem Cell Self-Renewal and Erythroid Differentiation , 2004, The Journal of experimental medicine.

[20]  J. Bennett,et al.  Diagnosis and treatment of systemic mastocytosis: state of the art , 2003, British journal of haematology.

[21]  Y. Terauchi,et al.  Role of phosphoinositide 3-kinase signaling in mast cells: new insights from knockout mouse studies , 2003, Journal of Molecular Medicine.

[22]  L. Bouton,et al.  Stat5 expression is critical for mast cell development and survival. , 2003, Blood.

[23]  Heinz Baumann,et al.  Signal transducer and activator of transcription proteins in leukemias. , 2003, Blood.

[24]  Olivier Hermine,et al.  Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms , 2003, Oncogene.

[25]  C. Sawyers,et al.  Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia , 2002, Current opinion in hematology.

[26]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[27]  H. Iwasaki,et al.  Critical role for Gab2 in transformation by BCR/ABL. , 2002, Cancer cell.

[28]  T. Hirano,et al.  Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. , 2002, Blood.

[29]  Shan Zeng,et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.

[30]  Tsutomu Takeuchi,et al.  Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice , 2002, Nature Immunology.

[31]  J. Ihle,et al.  Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. , 2002, Blood.

[32]  M. Tomasson,et al.  The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. , 2001, Blood.

[33]  D. Lauffenburger,et al.  Quantitative analysis of synthetic gene delivery vector design properties. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  E Leonard,et al.  Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. , 2001, Blood.

[35]  M. H. Nguyen,et al.  TEL-JAK2 Mediates Constitutive Activation of the Phosphatidylinositol 3′-Kinase/Protein Kinase B Signaling Pathway* , 2001, The Journal of Biological Chemistry.

[36]  J. C. Pratt,et al.  Essential role for Gab2 in the allergic response , 2001, Nature.

[37]  D. Metcalfe,et al.  Mastocytosis: molecular mechanisms and clinical disease heterogeneity. , 2001, Leukemia research.

[38]  K. Austen,et al.  Mast cell lineage development and phenotypic regulation. , 2001, Leukemia research.

[39]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[40]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[41]  W. Jurecka,et al.  Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). , 2001, Human pathology.

[42]  P. Charneau,et al.  Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[44]  M. Loh,et al.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.

[45]  D. Metcalfe,et al.  Kit signal transduction. , 2000, Hematology/oncology clinics of North America.

[46]  R. Berger,et al.  Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. , 2000, Blood.

[47]  B. Foster,et al.  Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). , 1999, Blood.

[48]  S. Galli,et al.  Mast cells as sentinels of innate immunity. , 1999, Current opinion in immunology.

[49]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[50]  J. Ryan,et al.  Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells. , 1997, Experimental hematology.

[51]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[52]  J. Griffin,et al.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.

[53]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  O. Majdic,et al.  Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. , 1993, Journal of immunology.

[55]  D. Metcalfe,et al.  IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand. , 1993, Journal of immunology.

[56]  K. Zsebo,et al.  Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. , 1992, Blood.

[57]  D. Metcalfe,et al.  Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. , 1991, Journal of immunology.

[58]  P. Leder,et al.  The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus , 1990, Cell.

[59]  D. Housman,et al.  The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene , 1988, Cell.

[60]  S. Hsu,et al.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.

[61]  Y. Kitamura,et al.  Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes , 1981, Nature.

[62]  Y. Kitamura,et al.  Decreased production of mast cells in S1/S1d anemic mice. , 1979, Blood.

[63]  Y. Kitamura,et al.  Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. , 1978, Blood.

[64]  M. Djokic.  Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation , 2009 .

[65]  E. Wagner,et al.  Stat5 tetramer formation is associated with leukemogenesis. , 2005, Cancer cell.

[66]  D. Metcalfe,et al.  Systemic mastocytosis. , 2004, Annual review of medicine.

[67]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.